Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.

Hugdahl E, Bachmann IM, Schuster C, Ladstein RG, Akslen LA.

PLoS One. 2019 Jan 14;14(1):e0210399. doi: 10.1371/journal.pone.0210399. eCollection 2019.

2.

Malignant melanoma--diagnosis, treatment and follow-up in Norway.

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA.

Tidsskr Nor Laegeforen. 2013 Oct 29;133(20):2154-9. doi: 10.4045/tidsskr.12.1416. Review. English, Norwegian.

3.

Nestin expression is associated with aggressive cutaneous melanoma of the nodular type.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

Mod Pathol. 2014 Mar;27(3):396-401. doi: 10.1038/modpathol.2013.151. Epub 2013 Sep 13.

4.

Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.

Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A.

J Med Genet. 2013 Apr;50(4):264-70. doi: 10.1136/jmedgenet-2012-101455. Epub 2013 Feb 5. Erratum in: J Med Genet. 2014 Mar;51(3):214.

5.

Tumor necrosis is a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

Am J Surg Pathol. 2012 Oct;36(10):1477-82. doi: 10.1097/PAS.0b013e31825a5b45.

PMID:
22982891
6.

Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

J Invest Dermatol. 2012 Apr;132(4):1247-52. doi: 10.1038/jid.2011.464. Epub 2012 Feb 2.

7.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

8.

Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA.

BMC Cancer. 2008 Dec 5;8:362. doi: 10.1186/1471-2407-8-362.

9.

Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.

Bachmann IM, Puntervoll HE, Otte AP, Akslen LA.

Mod Pathol. 2008 May;21(5):583-90. doi: 10.1038/modpathol.2008.17. Epub 2008 Feb 8.

10.

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A.

Melanoma Res. 2008 Feb;18(1):29-35. doi: 10.1097/CMR.0b013e3282f32517.

PMID:
18227705
11.

Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.

Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14.

12.

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA.

J Clin Oncol. 2006 Jan 10;24(2):268-73. Epub 2005 Dec 5.

PMID:
16330673
13.

BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.

Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R.

J Invest Dermatol. 2005 Aug;125(2):312-7.

14.

Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.

Bachmann IM, Straume O, Akslen LA.

Int J Oncol. 2004 Dec;25(6):1559-65.

PMID:
15547691

Supplemental Content

Loading ...
Support Center